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Benidipine hydrochloride, used as an antihypertensive agent and long-acting calcium antagonist, is
synthesized for commercial use as a drug substance in highly pure form. During the synthetic process
development studies of benidipine, process related impurities were detected. These impurities were
identiﬁed, synthesized and characterized and mechanisms of their formation were discussed in detail.
After all standardization procedures, they were used as reference standards for analytical studies. In
addition, a separate HPLC method was developed and validated for detection of residual 1-benzylpi-
peridin-3-ol (Ben-2), which is used during benidipine synthesis and controlled as a potential process
related impurity. As complementary of this work, stress-testing studies of benidipine were carried out
under speciﬁed conditions and a stability-indicating UPLC assay method was developed, validated and
used during stability studies of benidipine.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Benidipine hydrochloride, (7)-(4Rn)-3-(Rn)-1-benzylpiperidin-
3-yl 5-methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyr-
idine-3,5-dicarboxylate hydrochloride, is a racemic mixture of two
isomers RR-() and SS-(þ) and called α-benidipine hydrochloride
(Fig. 1).
Benidipine is a dihydropyridine vasoselective long acting cal-
cium channel blocker developed in Japan [1]. It blocks three dif-
ferent types of calcium channels (L, N and T) in the cell membrane
by its unique mechanism of action. Benidipine has different unique
chemical properties compared to the other calcium channel
blocker agents [2], such as strong and long acting effect due to its
high afﬁnity and unique membrane binding sites, renal protective
effect due to its triple (L, N and T) calcium channel blockage, and
cardioprotective and vasoprotective effect due to its vascular se-
lectivity and positive effect on nitric oxide production. As a solid,
benidipine hydrochloride is stable to variations in heat and
moisture, and is fairly stable to light exposure [3].
Several methods are reported in the literature [4] for synthesis
of benidipine hydrochloride. Our synthesis method for benidipine
hydrochloride is given in Scheme 1. During the synthesis andon and hosting by Elsevier B.V. All
University.
3; fax: þ90 282 7581770.
@yahoo.com (E. Bellur Atici).puriﬁcation stages of benidipine hydrochloride, process related
impurities were consistently observed in HPLC analyses. A few
analytical methods have been reported in the literature for the
determination of benidipine including studies related to its tablet
and plasma concentrations [5–10].
As per the general guidelines recommended by the Interna-
tional Conference on Harmonisation (ICH) [11,12] to qualify the
drug substance, the amount of acceptable level for a known and
unknown related compound (impurity) should be less than 0.15%
and 0.10%, respectively. In order to meet the stringent regulatory
requirements, impurities should be identiﬁed and their amounts
should be controlled carefully. In recent years, the impurity proﬁle
of a drug substance has become more important for marketing
approval and this work is done as part of a drug development
process [13–21]. Of course, it is a challenging work for the devel-
opment team to identify the impurities formed in very small
quantities in a drug substance. Since mostly it is difﬁcult to
identify and control impurities within speciﬁed limits and addi-
tional puriﬁcation steps may then be applied, it makes the process
less competitive. Most of the impurities are not commercially
available and they should be synthesized by the development
team, which is not so easy since their syntheses are not known or
not described in the literature. To the best of our knowledge, there
is no report in the literature for the identiﬁcation and synthesis of
the impurities of benidipine. We believe that development of a
drug substance is incomplete without the identiﬁcation of anrights reserved. This is an open access article under the CC BY-NC-ND license
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explored the formation, identiﬁcation, synthesis and character-
ization of impurities found in the synthesis of benidipine. This
study will be of immense help for pharmaceutical development
teams to understand the potential impurities in benidipine
synthesis and thereby obtain the pure compound.N
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Fig. 1. Chemical structure of α-benidipine hydrochloride.
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Scheme 1. Synthesis of benThe impurities observed on HPLC analyses during the process
development of benidipine (Fig. 1) were identiﬁed by LC–MS. After
thorough evaluation of the benidipine synthetic route (Scheme 1),
all plausible side reactions were determined, and these reactions
were carried out separately to synthesize the related impurities of
benidipine hydrochloride. The synthesis and characterization of
benidipine impurities were carried out and reported herein, to-
gether with the discussion on pathway of their formation. In ad-
dition, due to its highly polar property, a separate HPLC method
was developed and validated for detection of residual 1-benzyl-
piperidin-3-ol (Ben-2), which was used during benidipine synth-
esis and controlled as a potential impurity.
The purpose of stability testing is to provide evidence on how
the quality of a drug substance varies with time under the inﬂu-
ence of a variety of environmental factors, such as temperature,
humidity, and light, and to establish a retest period for the drug
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benidipine were carried out under speciﬁed conditions and a
stability-indicating UPLC assay method was developed, validated
and used during stress-testing and stability studies of benidipine.
Unlike the known assay method for benidipine hydrochloride
dependent on potentiometric titration [24] and not useful for as-
say analyses of stress-testing studies, our developed method is a
stability-indicating, rapid, reliable, safe and clean method in terms
of the chemicals used in both methods.2. Experimental
2.1. Chemicals, reagents and samples
Benidipine hydrochloride samples were taken from commercial
batches produced by Deva Holding A.Ş. (Tekirdag˘, Turkey), or
synthesized in the R&D laboratories of Deva. Benidipine hydro-
chloride standard was supplied by a specialized team on stan-
dardization of reference standards for analytical use in Deva.
Synthetic and analytical reagents and solvents were supplied from
different chemical companies such as potassium dihydrogen
phosphate, phosphoric acid, hydrochloric acid (37%), sodium hy-
droxide, hydrogen peroxide (30%), thionyl chloride, sulfuric acid
(conc.) and sodium hydrogen carbonate from Merck KGaA
(Darmstadt, Germany); tetrahydrofuran (THF), dichloromethane,
acetonitrile, methanol, ethanol and acetone from J.T. Baker (Phil-
lipsburg, USA); diethyl ether and ethyl acetate from Lab-Scan
(Gliwice, Poland); chromium (VI) oxide (CrO3) from Sigma-Aldrich
(St. Louis, MO, USA); potassium hydroxide from Acros Organics
(Geel, Belgium); dimethyl formamide from Akkim (Yalova, Tur-
key); anhydrous sodium sulfate from Sodas Sodyum Sanayi A.S.
(Izmir, Turkey), and sodium chloride from Emekcioglu Tuz A.S.
(Ankara, Turkey). Deionized water was prepared using MilliQ plus
puriﬁcation system (Millipore, Bedford, MA, USA). Deuterated
solvents (dimethylsulfoxide-d6 and deuterated chloroform) were
purchased from Merck KGaA (Darmstadt, Germany).
2.2. Liquid chromatography (HPLC and UPLC)
Chromatographic separations were performed on HPLC system
with Waters Alliance 2695 separation module equipped with a
Waters 996 photodiode array detector and an Empower-pro data
handling system (Waters Corporation, Milford, MA, USA).
The analysis of all compounds excluding Ben-2 was carried out
on C18 (100 mm4.6 mm, 3 mm) column (Hypersil BDS) at 25 °C
with phosphate-buffer/methanol/THF (65/27/8) mixture ﬂowing
at a rate of 0.75 mL/min (it was adjusted during the analysis so
that the retention time of benidipine was about 20 min) during
60 min. Buffer solution was prepared by dissolving 6.8 g of po-
tassium dihydrogen phosphate in 1000 mL water and pH was
adjusted to 3.070.05 with 30% phosphoric acid. The injection
volume and detection wavelength were ﬁxed at 10 mL and 237 nm,
respectively. Test solution was prepared by dissolving 20.0 mg of
sample in 100.0 mL diluent (0.2 mg/mL) and methanol/water (50/
50) mixture or methanol was used as diluent.
The analysis for determination of Ben-2 impurity in benidipine
was carried out on C1 (250 mm4.6 mm, 5 mm) column (ACE C1)
at 25 °C with mobile phase ﬂowing at a rate of 1.0 mL/min for
27 min. The separation was employed using gradient elution with
phosphate-buffer (mobile phase A) and acetonitrile (mobile phase
B) based on the following program: time (min)/% of mobile phase
B: 0/10, 6/10, 15/60, 20/60, 21/10, 27/10 and the dwell volume of
the equipment was 650 mL. Buffer solution was prepared by dis-
solving 6.8 g of potassium dihydrogen phosphate in 1000 mL wa-
ter and pH was adjusted to 6.070.05 with 10% potassiumhydroxide. The injection volume and detection wavelength were
ﬁxed at 10 mL and 210 nm, respectively. Test solution (1.0 mg/mL)
was prepared by dissolving 50.0 mg of benidipine hydrochloride in
50.0 mL methanol/water (50/50) mixture and the concentration of
Ben-2 reference solution was 1.0 mg/mL.
Assay studies were performed on Waters Acquity UPLC system
equipped with a Waters TUV detector and an Empower-pro data
handling system (Waters Corporation, Milford, MA, USA). The
analysis was carried out on BEH Shield RP18 (100 mm2.1 mm,
1.7 μm) column (Waters Acquity) with 1 mL injection volume at a
wavelength of 237 nm and with phosphate-buffer/acetonitrile (60/
40) mixture ﬂowing at a rate of 0.3 mL/min during 5 min. Column
and sample temperatures were 30 °C and 25 °C, respectively.
Buffer solution was prepared by dissolving 6.8 g of potassium di-
hydrogen phosphate in 1000 mL water and pH was adjusted to
3.070.05 with 30% phosphoric acid. Methanol/water (50/50) was
used as diluent. Test and standard solutions were prepared by
dissolving 20.0 mg of sample and reference standard, respectively,
in 100 mL of diluent (0.2 mg/mL).
2.3. Mass spectrometry
The mass spectra were recorded on Waters LC–MS ZQ 2000/
4000 system (Waters Corporation, Milford, MA, USA). The frag-
mentation proﬁle of the samples was established by carrying out
MS studies in positive or negative electrospray ionization (ESI)
mode. For LC–MS identiﬁcation of the impurities, the HPLC
method given above was used. The samples of the synthesized
compounds were directly infused using a syringe at a concentra-
tion of 1 mg/mL in methanol.
2.4. NMR spectroscopy
1H, 13C and DEPT NMR experiments were performed on a
300 MHz NMR Spectrometer (Varian NMR Instruments, Oxford,
UK; later acquired by Agilent Technologies, Santa Clara, CA, USA)
using deuterated dimethylsulfoxide (DMSO-d6) and deuterated
chloroform (CDCl3) as solvent and tetramethylsilane (TMS) as an
internal standard.
2.5. FT-IR spectroscopy
Samples were measured as neat by ATR (Attenuated Total Re-
ﬂectance) on Shimadzu FTIR Spectrometer IR Prestige-21 (Shi-
madzu Corporation, Kyoto, Japan) in the range of 600–4000 cm1
with 20 scans and 2 cm1 resolution.
2.6. Differential scanning calorimetry (DSC) and melting point
determination
DSC measurements were carried out using a Shimadzu DSC-60
instrument (Shimadzu Corporation, Kyoto, Japan). The instrument was
calibrated for temperature and heat ﬂow using indium and zinc
standards. The samples (2–3mg) were placed in sealed aluminum
pans under nitrogen purge at a ﬂow rate of 30 mL/min. The samples
were heated from 100 °C to 220 or 300 °C depending on the melting
range of the compound at a heating rate of 10 °C/min. Data acquisition
and analysis were performed using the Shimadzu TA-60WS software.
Start and end points for the integration of the thermal peak were
identiﬁed by visual inspection. The amounts of samples were weighed
in a Sartorius analytical balance model ME235S (Sartorius AG, Got-
tingen, Germany), with a resolution of 0.01mg. Melting points were
determined on an Electrothermal 9100 digital melting point instru-
ment (Thermo Fisher Scientiﬁc, Essex, UK).
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2.7.1. Synthesis of α- and β-benidipine hydrochloride (Scheme 1)
2.7.1.1. Synthesis of α-benidipine hydrochloride. 1,4-Dihydro-2,6-
dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-me-
thyl ester (Ben-1) (1.00 equiv.) was suspended in dichloromethane
and dimethyl formamide (4:1) mixture and the suspension was
cooled to 0–5 °C. Thionyl chloride (1.20 equiv.) was added to this
mixture and stirred for 1 h. Then, 1-benzyl-3-piperidinol (Ben-2)
(1.10 equiv.) was added into the reaction mixture and stirred for
2 h at 0–5 °C and 1 h at 25 °C. The reaction was quenched by ad-
dition of water. Organic phase was separated, washed with brine,
dried over anhydrous sodium sulfate and ﬁltered. The ﬁltrate was
concentrated to dryness under vacuum and the residue was
crystallized in ethanol and acetone mixture. The crude product
was ﬁltered and dried under vacuum. After several recrystalliza-
tion processes applied using ethanol and acetone, pharmaceutical
grade α-benidipine hydrochloride was obtained as yellowish
crystalline powder with overall 45% yield.
2.7.1.2. Isolation of β-benidipine hydrochloride (β-isomer impurity).
All crystallization ﬁltrates were combined during the benidipine
hydrochloride synthesis (Section 2.7.1.1) and concentrated to a
volume until β-isomer started to crystallize. The suspension was
stirred for 2 days at room temperature and ﬁltered to obtain β-
benidipine hydrochloride as yellowish crystalline powder (36%).
2.7.2. Synthesis of Ben-ox impurity (3-(1-benzylpiperidin-3-yl)
5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate
hydrochloride) (Scheme 2)
To the suspension of benidipine hydrochloride (1.00 equiv.) in
acetone, Jones reagent [25] (prepared by dissolving 81 g of CrO3 in
69 mL of concentrated sulfuric acid followed by cautious dilution
with water to 300 mL) was added at 0–5 °C and the suspension
was completely dissolved. After completion of the reaction (con-
trol by HPLC) in approximately 1 h, the reactionwas neutralized by
addition of saturated aqueous sodium hydrogen carbonate solu-
tion and the reaction mixture was extracted with ethyl acetate.
Organic extract was washed with brine, dried over anhydrous
sodium sulfate and ﬁltered. The ﬁltrate was concentrated to dry-
ness under vacuum. The residue was dissolved in diethyl ether and
washed with saturated aqueous sodium hydrogen carbonate so-
lution. The organic phase was dried over anhydrous sodium sulfate
and ﬁltered, and the ﬁltrate was concentrated to dryness under
vacuum. The product Ben-ox base “3-(1-benzylpiperidin-3-yl)
5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarbox-
ylate” was obtained as dark yellowish/brownish viscous oil
(99.6%). The product was then converted to its hydrochloride salt
by hydrochloric acid treatment in dichloromethane, dried over
anhydrous sodium sulfate and ﬁltered. The ﬁltrate was con-
centrated to dryness under vacuum to obtain the product Ben-ox “3-
(1-benzylpiperidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyr-
idine-3,5-dicarboxylate hydrochloride” as slightly yellowish foamy
powder (97.4%).
2.7.3. Synthesis of Ben-bis impurity (bis(1-benzylpiperidin-3-yl) 1,4-
dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate
dihydrochloride) (Scheme 3)
2.7.3.1. Synthesis of Ben-1 acid “1,4-dihydro-2,6-dimethyl-4-(3-ni-
trophenyl)pyridine-3,5-dicarboxylic acid”. Suspension of Ben-1 “5-
(methoxycarbonyl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)
pyridine-3-carboxylic acid” (1.00 equiv.) in water was cooled to 0–
5 °C and potassium hydroxide pellets (15.0 equiv.) were added
slowly. After the addition, the mixture was allowed to warm to
ambient temperature and stirred until completion of the ester
hydrolysis, which was monitored by HPLC and took around 6–7days. The reaction mixture was then ﬁltered and the ﬁltrate was
washed with diethyl ether, ethyl acetate, and dichloromethane,
respectively. Aqueous phase was cooled to 0–5 °C and neutralized
by addition of concentrated hydrochloric acid. The formed sus-
pension was stirred at this temperature for 10 min, ﬁltered, wa-
shed with water and dried under vacuum to obtain Ben-1 acid
“1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-di-
carboxylic acid” as beige powder (62%).
2.7.3.2. Synthesis of Ben-bis impurity. Ben-1 acid “1,4-dihydro-
2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid”
(1.00 equiv.) was suspended in dichloromethane and dimethyl
formamide (4:1) mixture and the suspension was cooled to 0–5 °C.
Thionyl chloride (2.40 equiv.) was added to this mixture and stir-
red for 1 h. Then, Ben-2 “1-benzyl-3-piperidinol” (2.20 equiv.) was
added into the reaction mixture and stirred for 2 h at 0–5 °C and
for 1 h at 25 °C. The reaction was quenched by addition of water.
Organic phase was separated, washed with brine, dried over an-
hydrous sodium sulfate and ﬁltered. The ﬁltrate was concentrated
to dryness under vacuum and the residue was crystallized in
ethanol and acetone mixture. The product was ﬁltered and dried
under vacuum to obtain Ben-bis “bis(1-benzylpiperidin-3-yl) 1,4-
dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarbox-
ylate dihydrochloride” as slightly yellowish powder (20%).
2.7.4. Synthesis of Ben-desbenzyl impurity (3-methyl 5-piperidin-3-
yl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarbox-
ylate hydrochloride) (Scheme 4)
Ben-1 “1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedi-
carboxylic acid 3-methyl ester” (1.00 equiv.) was suspended in
dichloromethane and dimethyl formamide (4:1) mixture and the
suspension was cooled to 0–5 °C. Thionyl chloride (1.20 equiv.)
was added to this mixture and stirred for 1 h. Then, piperidin-3-ol
(1.10 equiv.) was added into the reaction mixture and stirred for
2 h at 0–5 °C and for 1 h at 25 °C. The reaction was quenched by
addition of water. The organic phase was separated, washed with
brine, dried over anhydrous sodium sulfate and ﬁltered. The ﬁl-
trate was concentrated to dryness under vacuum and the residue
was crystallized in ethanol and acetone mixture. The product was
ﬁltered and dried under vacuum to obtain Ben-desbenzyl “3-me-
thyl 5-piperidin-3-yl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)
pyridine-3,5-dicarboxylate hydrochloride” as a slightly yellowish
powder (25%).
2.8. Stress-testing and stability studies
Benidipine was subjected to stress-testing under the following
conditions: neutral hydrolysis (stirring in water at 100 °C for 4 h),
alkaline hydrolysis (stirring in 1.0 M NaOH solution at 25 °C for
4 h), acidic hydrolysis (stirring in 1.0 M HCl solution at 25 °C for
4 h), oxidative degradation (stirring in 3% H2O2 solution at 25 °C
for 4 h); thermal (standing at 100 °C for 3 days), photolytic de-
gradation under UV-light (standing under near ultraviolet lamp
(254–400 nm, NLT 200 W h/m2) at 25 °C for 3 days) and day-light
(standing under cool white ﬂuorescent lamp (1.2 million lx h) at
25 °C for 3 days). The degraded samples were neutralized (for
acidic and basic hydrolysis) and diluted to obtain 0.2 mg/mL so-
lutions. Then, the samples were analyzed to determine the formed
degradation impurities and benidipine amount remained. For each
study, the corresponding blank solutions were prepared. Stability
studies were conducted under accelerated (4072 °C, 75%75%
humidity) and long-term (2572 °C, 60%75% humidity) condi-
tions, and samples were analyzed according to the related sub-
stances and assay methods reported herein.
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3.1. Detection and identiﬁcation of impurities
A typical analytical HPLC chromatogram of a production batch
of benidipine bulk drug spiked with impurities is shown in Fig. 2.
The impurities (marked as Ben-desbenzyl, Ben-bis, Ben-ox, β-iso-
mer and Ben-1) were detected in the crude sample of benidipine
during process development studies and their identiﬁcation was
performed by LC-MS. They were subsequently synthesized to ob-
tain sufﬁcient quantities for full characterization and further
analytical studies. All synthesized impurities were co-injected
with benidipine to conﬁrm the identity of the impurities based on
retention time matching (Fig. 2). Also, they were separately spiked
inside of the crude benidipine samples where they appeared as an
impurity on HPLC chromatograms. All impurities were well re-
solved from benidipine and each other. Retention time (RT, min),
relative retention times (RRT) of the impurities with respect to
benidipine, purity, DSC peak or melting point, IR and mass data,
and structures are shown in Table 1 and Fig. 3, respectively. 1H and
13C NMR assignments for benidipine and its impurities are shown
in Tables 2 and 3, respectively.
3.2. Structure elucidation and formation of impurities
The impurity at RT 26.96 min was very rarely observed in the
crude product during laboratory trials in the range of 0.05%–0.50%
and never observed in commercial productions after optimization
of the reaction and recrystallization steps of the process. The ESI
mass spectrum exhibited a molecular ion at m/z 331 in negative
ion mode, indicating molecular weight of 332, which was 173 amu
lower than that of benidipine. According to the mass data, this
impurity was identiﬁed as one of the benidipine intermediates
called “5-(methoxycarbonyl)-1,4-dihydro-2,6-dimethyl-4-(3-ni-
trophenyl)pyridine-3-carboxylic acid” and named as Ben-1 im-
purity (Fig. 3, Scheme 1). Ben-1 is a process related impurity and
may be found in the crude benidipine samples in case of in-
complete reaction. High-purity Ben-1 was prepared, fully char-
acterized and standardized for further analytical studies.
The impurity at RT 23.12 min was observed in crude benidipine
during process development studies and commercial productions.
The ESI mass spectrum exhibited a molecular ion at m/z 506 in
positive ion mode, indicating molecular weight of 505, which is
identical to that of benidipine. Its UV spectrum was also similar to
the benidipine spectrum and it was the main impurity observed in
the crude product samples, almost 30%–40% before the processFig. 2. HPLC analysis of benidipoptimization. As we know, benidipine has two stereogenic centers
and these stereocenters cause four enantiomers and two diaster-
eomers which are called α-benidipine (RR and SS racemic mixture)
and β-benidipine (RS and SR racemic mixture) (Fig. 3, Scheme 1).
According to the benidipine synthesis given in Scheme 1, reaction
resulted in the formation of both α- and β-benidipine almost in a
one-to-one ratio. α-Benidipine is the diastereomer that is used as
an active pharmaceutical ingredient and observed at 20.38 min on
HPLC chromatogram given in Fig. 2. Due to the solubility differ-
ences between α- and β-isomers, β-isomer was successfully re-
moved by optimized crystallization processes; even crude product
contained a small amount of this side product just after one
crystallization process following the reaction. Under the light of all
these information and spectral data, it was clariﬁed that the im-
purity at RT 23.12 min was β-isomer of benidipine. This side pro-
duct was isolated from crystallization ﬁltrates of benidipine, fully
characterized and standardized for analytical use.
The ESI mass spectrum exhibited a molecular ion at m/z 504 in
positive ion mode, indicating molecular weight of 503, which was
2 amu lower than that of benidipine. This difference could be ex-
plained by oxidation of the 1,4-dihydropyridine moiety of beni-
dipine to pyridine, which is commonly seen on the other 1,4-di-
hydropyridines used as an API in the pharmaceutical industry [26].
The impurity observed at RT 15.89 min was identiﬁed as oxidation
impurity “3-(1-benzylpiperidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-
nitrophenyl)pyridine-3,5-dicarboxylate” and named as Ben-ox
impurity (Fig. 3, Scheme 2), which was very rarely found in the
crude product during process development studies (o0.05%),
never observed in commercial productions and observed in the
product during stability studies (0.05%–0.10%). This process related
impurity was synthesized from benidipine by aromatization of the
1,4-dihydropyridine ring to pyridine, fully characterized and
standardized for analytical use. Compared with benidipine NMR
spectra, 1H NMR spectrum (DMSO-d6) of Ben-ox impurity showed
no signals for positions 1 and 4 and 13C NMR and DEPT spectra
showed signal at 137.7 ppm (C) for position 4, which was 39.3 ppm
(CH) for benidipine. All spectral data conﬁrmed the structure of
Ben-ox impurity.
The ESI mass spectrum of the impurity observed at RT 8.55 min
exhibited a molecular ion at m/z 665 in positive ion mode, in-
dicating molecular weight of 664, which was higher by 159 amu
than that of benidipine. This difference could be explained by loss
of methyl group and addition of a second 1-benzylpiperidinyl
moiety to form “bis(1-benzylpiperidin-3-yl) 1,4-dihydro-2,6-di-
methyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate” (Fig. 3). This
impurity was named as Ben-bis and determined in all benidipineine spiked with impurities.
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purity was dependent on the content of a Ben-1 impurity called
Ben-1 acid “1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-
3,5-dicarboxylic acid”. Formation of Ben-1 acid as a by-product
during production of Ben-1 intermediate by alkaline ester hydro-
lysis of “dimethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyr-
idine-3,5-dicarboxylate” was expected (Scheme 1). According to
our synthetic and analytical studies, it was conﬁrmed that Ben-1
contains this dicarboxylic acid impurity in the range of 0.15%–
0.55%. Ben-1 acid impurity present in Ben-1 gave reaction with “1-
benzylpiperidin-3-ol (Ben-2)” from both sites and formed the Ben-Table 1
Retention time, relative retention time (RRT), purity, DSC peak or melting point, FTIR a
Compounda RT (min) RRT Purity (%) DSC peak
(°C)
IR (neat) (cm1)
Benidipine 20.38 1.0 99.95 203 3169, 3065 (w, aromatic C
(s, NO2), 1491 (s, CQC), 13
1098 (s, C–O–C), 1012 (s,
Ben-desbenzyl 7.94 0.39 97.60 220 3250, 3204 (w, aromatic C
1481 (s, CQC), 1381 (w, C
(s), 1082 (s, C–O–C), 1020
Ben-bis 8.55 0.42 99.62 263 3179, 3071 (w, aromatic C
1496 (s, CQC), 1346 (s, NO
746 (s), 716 (s), 702 (s, ar
Ben-1 acidb – – 99.18 194 3453 (w, N–H), 1674 (s, C
1317 (m), 1210 (s, C–O–C)
Ben-ox 15.89 0.78 99.10 125c 2951 (w, CH3, CH2), 2504
1288 (m, C–N), 1231 (s), 1
aromatic C–H)
β-isomer 23.12 1.13 98.96 243 3158, 3048 (w, aromatic C
CQC), 1384 (m, CH3, CH2
1017 (s, C–N–H), 982 (w),
Ben-1 26.96 1.32 99.46 219 3338 (w, N–H ), 1652 (s), 1
O–C), 1017 (m, C–N–H), 7
a Copies of spectra are presented in supporting Appendix A.
b Not considered as benidipine impurity.
c Melting point.
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Fig. 3. Structures of benidipbis impurity in benidipine. Ben-1 acid was then prepared by ester
hydrolysis of Ben-1, and reacted with Ben-2 under similar condi-
tions used for synthesis of benidipine to obtain the Ben-bis im-
purity (Scheme 3). Ben-1 acid and Ben-bis impurities were then
characterized and standardized for analytical use. Compared with
benidipine NMR spectra, 1H NMR spectrum (DMSO-d6) of Ben-bis
impurity showed doubled signals for the 1-benzylpiperidinyl
moiety and missed methoxy peak. 13C NMR and DEPT spectra
showed no methoxy peak, a single peak for both methyl groups
(positions 7 and 8) located on 1,4-dihydropyridine ring, and also a
single peak for carboxyl groups (positions 9 and 10) due to thend mass spectral data of benidipine and its impurities.
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Table 2
1H NMR assignments for benidipine and its impurities.
Positiona δ ppm
Benidipineb Ben-
desbenzylb
Ben-bisb Ben-1 acidb Ben-ox (base)c Ben-ox (HCl)c β-isomerb Ben-1b
1 9.19; 9.25
(ds, NH)
9.52 (s, NH) 9.32; 9.41
(ds, NH)
8.83 (s, NH) – – 9.18; 9.21
(ds, NH)
8.98 (s, NH)
4 4.84–5.07
(m, 1H)
5.16 (s, 1H) 5.19; 5.74
(ds, 1H)
4.95 (s, 1H) – – 4.81–4.92
(m, 1H)
5.00 (s, 1H)
7 2.24 (s, 3H) 2.53 (s, 3H) 2.26 (s, 3H) 2.25 (s, 3H) 2.87 (s, 3H) 2.55 (s, 3H) 2.215 (s, 3H) 2.28 (s, 3H)
8 2.26 (s, 3H) 2.51 (s, 3H) 2.26 (s, 3H) 2.25 (s, 3H) 2.85 (s, 3H) 2.57 (s, 3H) 2.22 (s, 3H) 2.29 (s, 3H)
12 7.91–8.00
(m, 1H)
8.18 (s, 1H) 7.91–8.02
(m, 1H)
7.96 (s, 1H) 8.38 (s, 1H) 8.05 (s, 1H) 7.85–7.97
(m, 1H)
7.97 (s, 1H)
14 7.91–8.00
(m, 1H)
8.22 (d,
J¼8.1 Hz, 1H)
7.91–8.02
(m, 1H)
7.97 (d,
J¼7.8 Hz, 1H)
8.38 (d,
J¼6.0 Hz, 1H)
8.17 (d,
J¼6.9 Hz, 1H)
7.85–7.97
(m, 1H)
8.01
(d, J¼8.1 Hz,
1H)
15 7.41–7.62
(m, 1H)
7.75 (t,
J¼7.8 Hz, 1H)
7.67–7.72
(m, 1H)
7.51 (t,
J¼7.8 Hz, 1H)
7.68 (t,
J¼8.1 Hz, 1H)
7.39–7.53
(m, 1H)
7.32–7.56
(m, 1H)
7.54
(t, J¼7.8 Hz,
1H)
16 7.41–7.62
(m, 1H)
7.83 (d,
J¼7.5 Hz, 1H)
7.67–7.72
(m, 1H)
7.57 (d,
J¼7.8 Hz, 1H)
7.80 (d,
J¼8.1 Hz, 1H)
7.39–7.53
(m, 1H)
7.32–7.56
(m, 1H)
7.60
(d, J¼7.2 Hz,
1H)
17 3.50 (s, 3H) 3.75 (s, 3H) – 11.79 (br, OH) 3.82 (s, 3H) 3.54 (s, 3H) 3.47 (s, 3H) 3.56 (s, 3H)
18 4.84–5.07
(m, 1H)
5.08 (m, 1H) 4.85–5.08
(m, 2H)
11.79 (br, OH) 5.06 (quint,
J¼4.1 Hz, 1H)
5.27–5.45
(m, 1H)
4.81–4.92
(m, 1H)
11.89 (s, OH)
19 2.70–3.42
(m, 2H)
3.06–3.15
(m, 1H),
3.23–3.33
(m, 1H)
2.72–3.29
(m, 4H)
– 2.10–2.28
(m, 1H),
2.64–2.70
(m, 1H)
2.20–2.45
(m, 1H),
2.79–3.08
(m, 1H)
2.60–3.00
(m, 2H)
–
20 10.06; 11.12
(dbr, NH)
9.41 (br, NH2) 10.25; 11.41
(dbr, 2NH)
– – 12.8 (br, NH) 9.95; 11.03
(dbr, NH)
–
21 2.70–3.42
(m, 2H)
3.06–3.15
(m, 1H),
3.23–3.33
(m, 1H)
2.72–3.29
(m, 2H),
3.45–3.60
(m, 2H)
– 2.30–2.41
(m, 1H),
2.59–2.63
(m, 1H)
2.20–2.45
(m, 1H),
3.30–3.34
(m, 1H)
2.60–3.00
(m, 1H),
3.01–3.26
(m, 1H)
–
22 1.32–2.09
(m, 2H)
2.00–2.12
(m, 2H)
1.59–1.68
(m, 2H),
1.72–2.08
(m, 2H)
– 1.31–1.41
(m, 1H),
1.80–1.98
(m, 1H)
1.70–1.85
(m, 1H),
2.20–2.45
(m, 1H)
1.72–1.88
(m, 1H),
1.92–2.02
(m, 1H)
–
23 1.32–2.09
(m, 2H)
1.82–1.92
(m, 2H)
1.37–1.42
(m, 2H),
1.72–2.08
(m, 2H)
– 1.70–1.77
(m, 1H),
1.80–1.98
(m, 1H)
1.09–1.22
(m, 1H),
1.70–1.85
(m, 1H)
1.36–1.48
(m, 1H),
1.72–1.88
(m, 1H)
–
24 4.19–4.37
(m, 2H)
– 4.23–4.47
(m, 4H)
– 3.62–3.69
(m, 2H)
4.40 (s, 2H) 4.11–4.35
(m, 2H)
–
26, 27, 28 7.41–7.62
(m, 5H)
– 7.44–7.64
(m, 5H)
– 7.48-7.60
(m, 5H)
7.39–7.53
(m, 5H)
7.32–7.56
(m, 5H)
–
Assignments: s: singlet; d: doublet; t: triplet; quint: quintet; m: multiplet; and br: broad singlet.
a Numbering of benidipine and the impurities shown in Fig. 3 and copies of NMR spectra are presented in supporting Appendix A.
b Solvent is DMSO-d6.
c Solvent is CDCl3.
E. Bellur Atici, B. Karlığa / Journal of Pharmaceutical Analysis 5 (2015) 256–268262symmetric structure of the molecule. All spectral data conﬁrmed
the structure of Ben-bis impurity, which was observed in all be-
nidipine batches during process development studies and com-
mercial productions. Production process was especially optimized
to eliminate this impurity and its amount was successfully reduced
under 0.10% in the ﬁnal product.
The ESI mass spectrum of the impurity observed at RT 7.94 min
exhibited a molecular ion at m/z 416 in positive ion mode, in-
dicating molecular weight of 415, which was 89 amu lower than
that of benidipine. This difference could be explained by loss of
benzyl group located on 1-benzylpiperidinyl moiety. This structure
corresponds to the molecule called “3-methyl 5-piperidin-3-yl 1,4-
dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarbox-
ylate” which was named as Ben-desbenzyl impurity (Fig. 3). This
impurity was formed by reaction of an impurity carried from
previous steps of the synthesis, as in the case of formation of Ben-
bis impurity. The possible pathway for formation of Ben-desbenzylimpurity could be explained by reaction of Ben-1 with “piperidin-
3-ol” impurity present in Ben-2. “Piperidin-3-ol” impurity was
formed during synthesis of Ben-2 by sodium borohydride reduc-
tion of the residual starting material “piperidin-3-one” present in
“1-benzylpiperidin-3-one”. “Piperidin-3-ol” reacted with Ben-1
under similar conditions used for synthesis of benidipine to obtain
the Ben-desbenzyl impurity (Scheme 4), which was then char-
acterized and standardized for analytical use. Compared with be-
nidipine NMR spectra, benzyl group signals were missed on both
1H NMR and 13C NMR spectra (DMSO-d6) of Ben-desbenzyl im-
purity. Also, higher amine (position 20) signal was found on 1H
NMR spectrum. All spectral data conﬁrmed the structure of Ben-
desbenzyl impurity, which was observed in few benidipine bat-
ches during process development studies, never observed after
optimization of the process conditions and during commercial
productions.
E. Bellur Atici, B. Karlığa / Journal of Pharmaceutical Analysis 5 (2015) 256–268 2633.3. Validation of HPLC method for determination of Ben-2
The method was validated according to ICH Q2 (R1) guideline
[27] and results of the validation study are given below.
3.3.1. System suitability
The system suitability was conducted throughout the validation
study by using 1 μg/mL reference solution (Ben-2) and evaluated by
making six replicate injections. The system was deemed to be sui-
table for use as the relative standard deviation (RSD) of the areas was
below 5.0%. The average of the areas was found as 22089 with
standard deviation (SD) 87 and RSD was calculated as 0.4%, con-
ﬁrming the injection repeatability of the developed method.Table 3
13C chemical shifts in benidipine and its impurities.
Positiona δ ppm (DEPT)
Benidipineb Ben-desbenzylb Ben-bisb Ben-1 acid
2 146.7 (C) 147.1 (C) 147.2 (C) 144.6 (C)
3 100.2 (C) 101.0 (C) 102.0 (C) 99.8 (C)
4 39.3 (CH) 40.2 (CH) 38.6 (CH) 38.3 (CH)
5 101.4 (C) 101.8 (C) 102.0 (C) 99.8 (C)
6 147.8 (C) 148.2 (C) 147.2 (C) 144.6 (C)
7 18.6 (CH3) 19.5 (CH3) 18.7 (CH3) 16.8 (CH3)
8 18.5 (CH3) 18.9 (CH3) 18.7 (CH3) 16.8 (CH3)
9 167.2 (C) 167.6 (C) 165.8 (C) 167.1 (C)
10 165.3 (C) 166.4 (C) 165.8 (C) 167.1 (C)
11 148.2 (C) 148.3 (C) 148.6 (C) 146.1 (C)
12 121.9 (CH) 122.4 (CH) 122.5 (CH) 119.5 (CH
13 150.1 (C) 150.6 (C) 151.4 (C) 148.8 (C)
14 121.5 (CH) 121.9 (CH) 121.6 (CH) 120.2 (CH
15 129.7 (CH) 130.3 (CH) 132.1 (CH) 128.2 (CH
16 134.4 (CH) 134.8 (CH) 135.2 (CH) 132.6 (CH
17 51.1 (CH3) 51.6 (CH3) – –
18 65.3 (CH) 66.0 (CH) 65.3 (2CH) –
19 52.5 (CH2) 45.7 (CH2) 52.4 (2CH2) –
21 50.7 (CH2) 43.2 (CH2) 52.1 (2CH2) –
22 19.9 (CH2) 19.9 (CH2) 18.8 (2CH2) –
23 27.7 (CH2) 27.8 (CH2) 25.7 (2CH2) –
24 59.3 (CH2) – 59.8 (2CH2) –
25 129.7 (C) – 130.0 (2C) –
26 131.7 (2CH) – 132.3 (4CH) –
27 128.9 (2CH) – 129.2 (4CH) –
28 129.9 (CH) – 130.7 (2CH) –
a Numbering of benidipine and the impurities shown in Fig. 3 and copies of NMR s
b Solvent is DMSO-d6.
c Solvent is CDCl3.
Benidipine hydrochloride
N
H
O
O
O
O
O2N
N
HCl
N
O
O
O
O
O2N
Ben-ox im
Jone
Reage
Aceton
Scheme 2. Synthesis o3.3.2. Speciﬁcity and stability
System suitability test was conducted and RSD value was found
to be 0.6%. The following injections were done for speciﬁcity test:
one diluent, two test solutions (1 mg/mL benidipine hydro-
chloride), and two test solutions spiked with Ben-2 at the speci-
ﬁcation limit (0.10%); no overlapping peak was observed on di-
luent chromatogram at the retention time of Ben-2. Thus, the
method was found speciﬁc for determination of Ben-2 in benidi-
pine. Stability of solutions was evaluated by injection of two re-
ference solutions and two test solutions spiked with Ben-2 at the
speciﬁcation limit freshly and then each 12 h for two days. Sam-
ples were accepted as stable for a time period during which the
difference between fresh and different period results was belowb Ben-ox (base)c Ben-ox (HCl)c β-isomerb Ben-1b
155.8 (C) 156.2 (C) 146.8 (C) 147.7 (C)
126.1 (C) 125.3 (C) 100.4 (C) 101.2 (C)
137.5 (C) 137.7 (C) 39.7 (CH) 39.8 (CH)
126.4 (C) 126.4 (C) 101.9 (C) 102.5 (C)
155.9 (C) 156.5 (C) 148.1 (C) 146.6 (C)
22.8 (CH3) 23.1 (CH3) 18.9 (CH3) 19.06 (CH3)
22.9 (CH3) 23.1 (CH3) 18.8 (CH3) 19.12 (CH3)
167.4 (C) 167.4 (C) 167.5 (C) 167.9 (C)
166.2 (C) 165.3 (C) 165.5 (C) 169.3 (C)
143.2 (C) 143.5 (C) 148.8 (C) 148.5 (C)
) 122.9 (CH) 122.9 (CH) 122.2 (CH) 121.9 (CH)
147.5 (C) 147.7 (C) 150.5 (C) 150.9 (C)
) 123.1 (CH) 123.6 (CH) 121.8 (CH) 122.4 (CH)
) 129.0 (CH) 131.4 (CH) 130.1 (CH) 130.5 (CH)
) 133.9 (CH) 134.2 (CH) 134.6 (CH) 134.8 (CH)
52.1 (CH3) 52.4 (CH3) 51.4 (CH3) 51.62 (CH3)
71.0 (CH) 67.3 (CH) 65.7 (CH) –
56.0 (CH2) 52.3 (CH2) 52.3 (CH2) –
52.6 (CH2) 51.2 (CH2) 51.3 (CH2) –
22.3 (CH2) 19.6 (CH2) 20.2 (CH2) –
28.8 (CH2) 27.5 (CH2) 28.3 (CH2) –
62.5 (CH2) 60.6 (CH2) 59.5 (CH2) –
137.7 (C) 127.8 (C) 129.9 (C) –
128.6 (2CH) 130.1 (2CH) 132.0 (2CH) –
128.0 (2CH) 129.2 (2CH) 129.2 (2CH) –
126.9 (CH) 129.6 (CH) 130.0 (CH) –
pectra are presented in supporting Appendix A.
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an RSD value of 1.3% and the samples were found stable up to 48 h.
3.3.3. Sensitivity (LOD and LOQ) and LOQ precision
The LOD and LOQ for Ben-2 impurity were estimated at a sig-
nal-to-noise ratio of 3:1 and 10:1, respectively, by injecting six
replicate reference solutions with 1 μg/mL concentration, and
calculated according to the following equations: LOD¼(3/SN)C;
LOQ¼(10/SN)C, where SN is signal-to-noise and C is con-
centration of the reference solution. LOD and LOQ were found to
be 0.003% (0.03 μg/mL) and 0.01% (0.09 μg/mL), respectively. RSD
value was found to be 0.4% (o5.0%) and LOQ was below the re-
porting level 0.05% and met the validation criterion. Precision at
the LOQ level was carried out by injecting six replicates of stan-
dard solution of Ben-2 at LOQ concentration. Average of the areas
was found as 2179 with standard deviation of 35, and RSD value of
1.6%, which was below the acceptance limit of 10.0%. Chromato-
grams of diluent, test solution spiked with Ben-2 at speciﬁcationN
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Scheme 4. Synthesis of Belimit (0.10%), LOD (Ben-2 conc. 0.03 μg/mL (0.003%)) and LOQ
(Ben-2 conc. 0.09 μg/mL (0.01%)) solutions are given in Fig. 4.
3.3.4. Linearity, range, accuracy, precision and robustness
System suitability test was conducted and the RSD value was
found to be 1.1%. Linearity test solutions of Ben-2 were prepared at
ﬁve concentration levels ranging from LOQ to 150% of the speci-
ﬁcation level (0.10%) and each sample was injected three times.
The peak area versus concentration data was analyzed with least
squares linear regression. Correlation coefﬁcient (r) and y-inter-
cept ratio to the response of target concentration were found to be
0.99996 (Z0.99) and 3.0% (r5.0%), respectively, indicating the
good linearity of the method. Solutions at level 1 (LOQ) and level 5
(150% of speciﬁcation limit) were injected six times, and RSD value
of areas was calculated for range study, and found to be 1.6% and
0.4%, respectively, below the acceptance limit of 5.0%. The accuracy
of the method was evaluated on test solutions spiked with Ben-2
in triplicate at three concentration levels of 0.49 μg/mL, 0.99 μg/mLN
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respectively). Good-to-excellent recoveries of Ben-2 (99.32–
100.45%) at each level were achieved within the limit range of
90.0%–110.0% (Table 4). Results for RSD and RSD of recoveries were
found below 5.0%, namely 0.4% and 3.2%, respectively. The preci-
sion of the method was investigated by injecting two individual
test solutions of benidipine hydrochloride (1 mg/mL) and six in-
dividual test solutions spiked with Ben-2 at the speciﬁcation limit
(0.10%). The same procedure was applied for the inter-day preci-
sion by a different analyst using different batch column and dif-
ferent instrument located within the same laboratory. The re-
coveries of Ben-2 for the intra-day and inter-day precision studies
were obtained in the range of 97.98%–101.01% and 96.26%–
100.93%, respectively. Results obtained for RSD of recoveries (1.12%
and 2.28%) were below 5.0% in both studies (Table 4). Difference of
the mean recoveries between two studies for intra-day and inter-
day precision was found to be 0.7% and the method was found to
be sufﬁciently precise since no signiﬁcant variation in the found
concentrations was observed on any day. Robustness of the
method was tested by changing the ﬂow rate by 10% (1.070.1 mL/
min), buffer pH by 70.2 units (6.070.2), and the column tem-
perature by 5 °C (2575 °C). In all of the above varied chromato-
graphic conditions, RSD was found below 1.6%, and no difference
was found between the normal and altered conditions, indicating
the robustness of the method.
Requirements for each stage of the validation study were ful-
ﬁlled. Thus, our developed method was precise, linear, accurate,
sensitive, selective and robust, and could be used for determina-
tion of Ben-2 impurity in benidipine drug substance. This method
was used to control residual Ben-2 as a potential impurity and to
date has not been detected in any of the manufactured benidipine
batches.
3.4. Validation of UPLC assay method
The known assay method for benidipine hydrochloride de-
pends on the potentiometric titration, and is performed by addi-
tion of formic acid and acetic anhydride, respectively, into theFig. 4. Chromatograms of HPLC method validation for determination of Ben-2 in benid
(0.10%), (C) LOD solution (Ben-2 conc. 0.03 μg/mL (0.003%)), and (D) LOQ solution (Ben-sample solution and titration of the resulting mixture with per-
chloric acid [24]. Unfortunately, this method is not stability-in-
dicating and selective to benidipine itself, since it depends on ti-
tration of the amine group and all amine containing molecules are
titrated including the impurities. Thus, it cannot be used for stress
and stability testing where it is necessary to reach the mass bal-
ance. Due to the necessity of a new stability-indicating assay
method for benidipine, we developed a method and validated it
according to ICH Q2 (R1) guideline [27].
3.4.1. System suitability
The system suitability was conducted throughout the assay
validation study by using standard benidipine hydrochloride so-
lution with a concentration of 0.2 mg/mL and evaluated by making
six replicate injections. The system was accepted to be suitable for
use as the relative standard deviation of the areas was below 0.85%
and the symmetry factor below 2.0. Average of the areas was
found as 1,638,857 with standard deviation (SD) 2326 and RSD
was calculated as 0.14%, conﬁrming the system suitability of the
developed method.
3.4.2. Speciﬁcity and stability
Speciﬁcity test was carried out by injections of three blank
solutions and two test solutions and no peak was observed on
diluent chromatogram at the retention time of benidipine. Stabi-
lity of the test solution was evaluated by injection of two different
test solutions freshly and then each 12 h for two days. Samples
were accepted as stable for a time period during which the dif-
ference between fresh and different period results is below 2.0%;
all assay results should be found in the range 98.0%–102.0% (on a
dry basis). For both solutions this difference did not exceed 0.19%
and all assay results were found in the range 98.3%–101.6%; thus
the test solution was found stable up to 48 h.
3.4.3. Linearity, range, accuracy, precision and robustness
Linearity test solutions of benidipine hydrochloride were pre-
pared at ﬁve concentration levels ranging from 80% to 120% of the
target concentration (0.2 mg/mL) and each sample was injectedipine: (A) blank solution, (B) test solution spiked with Ben-2 at speciﬁcation limit
2 conc. 0.09 μg/mL (0.01%)).
Table 4
Accuracy and precision studies of the HPLC method for determination of Ben-2 in benidipine hydrochloride.
Accuracy Precision
Intra-day (n¼6) Inter-day (n¼6)
Conc.
(μg/mL)
Conc. found
(Mean7SD,
μg/mL)
RSD
(%)
Recovery
(%)
Conc.
(μg/mL)
Conc. found
(Mean7SD,
μg/mL)
RSD
(%)
Recovery
(%)
Conc.
(μg/mL)
Conc. found
(Mean7SD,
μg/mL)
RSD
(%)
Recovery
(%)
0.49 0.4970.03 6.28 99.32 0.99 0.9870.01 1.12 98.99 1.07 1.0570.02 2.28 98.29
0.99 0.9870.01 0.59 99.33
1.48 1.4970.02 1.03 100.45
Table 5
Accuracy studies for benidipine hydrochloride UPLC assay method.
Level (%) Conc. (mg/mL) Conc. found (mg/mL) RSD (%) Recovery (%)
80 0.1615 0.1633 0.76 101.1
0.1611 0.1634 101.4
0.1600 0.1612 100.8
100 0.2059 0.2084 1.22 101.2
0.2032 0.2036 100.2
0.2048 0.2073 101.2
120 0.2415 0.2446 0.35 101.3
0.2417 0.2443 101.1
0.2408 0.2430 100.9
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with least squares linear regression. Correlation coefﬁcient (r) and
y-intercept ratio to the response of target concentration were
found as 0.99998 (Z0.999) and 1.9% (r2.0%), respectively, in-
dicating the good linearity of the method. Solutions at level 1
(0.16 mg/mL) and level 5 (0.24 mg/mL) were injected six times and
RSD of areas was calculated for range study, and found below the
acceptance limit of 0.85%, namely 0.18% and 0.10%, respectively.
The accuracy of the method was evaluated on test solutions pre-
pared in triplicate at three concentration levels (80%, 100% and
120% of the target concentration) and each solution was injected
twice. Good-to-excellent recoveries (100.2%–101.4%) at each level
were achieved within the limit range of 98.0%–102.0% and RSD of
recoveries was found to be 0.36% (Table 5).
The method precision of an analytical procedure expresses the
closeness of agreement between single results of the method ap-
plied repeatedly by the same analyst, using the homogeneous
sample, the same instrumentation and the same reagents. The
precision of the method was investigated by injecting six in-
dividual test solutions. The inter-day precision was conducted
according to the same procedure on a different day by a different
analyst using different batch columns and different instruments
located in the same laboratory. The assay results for intra-day and
inter-day precision studies were obtained in the range of 98.6%–
101.2% and 99.0%–100.3% (on dry basis), respectively. RSD values of
the results were found to be 0.98% and 0.44% (limit: 1.34%), re-
spectively. Difference between the mean of results obtained for
intra-day and inter-day precision (0.8%) was below the acceptance
limit of 2.0% as recommended by the ICH guideline, indicating that
the developed method was found to be precise. The robustness of
an analytical method is a measure of the effect of variable condi-
tions on analytical results in the process of analysis. For the de-
termination of the method's robustness, ﬂow rate, mobile phase
composition, pH of the buffer and column temperature were var-
ied within a realistic range and the effect of variations on analy-
tical procedure was examined and reported. Robustness of the
method was tested by changing the ﬂow rate by 10%
(0.3070.03 mL/min), buffer pH by 70.1 units (3.070.1), column
temperature by 7 5 °C (3075 °C), and the mobile phase acet-
onitrile composition by 72% (40%72%). In all of the above varied
chromatographic conditions, RSD and symmetry factors did not
exceed the limit values of 0.85% and 2.0, respectively, and were
found below 0.64% and 1.5, respectively. Assay results were ob-
tained in the range of 99.4%–100.6% (on dry basis), and difference
of the mean assay results between the normal and altered con-
ditions was found below 1.0% (limit: 2.0%), indicating the robust-
ness of the method.
The results showed that our developed assay method is spe-
ciﬁc, precise, accurate and robust, and it could be used for assay
analyses of benidipine manufacturing batches. The known po-
tentiometric titration method was also useful and successfully
used for assay analyses of benidipine batches parallel to thedeveloped UPLC method. But, unfortunately titration method was
not stability-indicating and could not be used for assay analyses of
benidipine during stress-testing and stability studies, where UPLC
method was applied successfully. Compared with the potentio-
metric method the UPLC method is faster (5 min run time), safer
and cleaner in terms of the chemicals used. The potentiometric
method is also problematic due to the use of acetic anhydride
which is in the controlled chemicals list of many countries and not
easy to import, and needs to be followed very carefully. The UPLC
assay method is also more reliable than potentiometric titration
and could be used for assay analyses of benidipine drug products
(tablets).
3.5. Stress-testing and stability studies
Stress-testing helps determine the intrinsic stability of the mole-
cule by establishing degradation pathways in order to identify the
likely degradation products and to validate the stability-indicating
power of the analytical methods used. The nature of the stress-testing
depends on the individual drug substance and the type of drug pro-
duct involved. In this study, degradation products of benidipine
formed under the inﬂuence of stress conditions were determined and
the degradation pathway was predicted. According to the results given
in Fig. 5 and Table 6, benidipine was not affected from light and it was
photo-stable; it was oxidized and formed Ben-ox impurity under
neutral and acidic hydrolysis and thermal conditions; the most serious
degradation was observed under oxidation condition where a new
degradation product was detected at around 29min (RRT 1.43) be-
sides the Ben-ox impurity. Peak purity test results obtained from a
PDA detector conﬁrmed that the benidipine peak was homogeneous
and pure in all of the analyzed stress samples, and the mass balance
results were in the range of 99.9%–100.2%. This study helped us during
selection of the packaging material and storage conditions of the drug
substance and also formulation studies of the drug product. Benidipine
was found stable after 6 months' storage at accelerated stability testing
conditions. Also, benidipine stayed stable after two years of storage at
normal conditions.
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In conclusion, all process related impurities of benidipine
hydrochloride produced according to the synthetic route given
in Scheme 1 were identiﬁed, synthesized and characterized.Fig. 5. Assay chromatograms (UPLC) of stress-testing studies: (A) untreated sample, (
hydrolysis (HCl), (G) basic hydrolysis (NaOH), and (H) oxidation (H2O2).
Table 6
Stress-testing and stability studies of benidipine.
Condition DP-I (%)
(RRT: 0.20)
Be
(%
Untreated sample ND 0.0
Thermal degradation (dry heat, 100 °C, 3 days) ND 0.0
Photolytic degradation – day-light (cool white ﬂuorescent lamp
(1.2 million lx h), 25 °C, 3 days)
ND 0.0
Photolytic degradation – UV-light (near ultraviolet lamp (254–
400 nm, NLT 200 W h/m2), 25 °C, 3 days)
ND 0.0
Neutral hydrolysis (water, 100 °C, 4 h) ND 0.0
Acid hydrolysis (1.0 M HCl, 25 °C, 4 h) ND 0.0
Base hydrolysis (1.0 M NaOH, 25 °C, 4 h) ND 0.0
Oxidative degradation (3% H2O2, 25 °C, 4 h) 0.07 0.0
Accelerated stability studies (75%75% humidity, 4072 °C,
6 months)
ND 0.0
Long-term stability studies (60%75% humidity, 2572 °C, 24
months)
ND 0.0
ND: not detected.
DP: degradation product.
a Mass balance: assayþtotal impurities.Structural elucidations of these compounds were done using
MS, IR and NMR (1H, 13C, DEPT) spectral data. Thus, the reg-
ulatory requirement has been fulﬁlled by characterizing all
those impurities and the prepared impurity standards have
been used during analytical method development andB) thermal, (C) day-light, (D) UV-light, (E) neutral hydrolysis (boiling), (F) acidic
n-bis
)
DP-II (%)
(RRT: 0.51)
Ben-ox
(%)
DP-III (%)
(RRT: 1.43)
Assay
(%)
Mass balance
(%)a
7 ND ND ND 100.0 100.1
5 ND 0.13 ND 99.7 99.9
5 ND ND ND 100.1 100.2
8 ND ND ND 99.8 99.9
7 ND 0.07 ND 100.0 100.1
8 0.09 0.07 ND 99.9 100.1
8 ND ND ND 99.8 99.9
6 ND 0.29 5.37 94.5 100.0
5 ND 0.08 ND 100.1 100.2
6 ND 0.08 ND 99.8 99.9
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stage of the process development and enabled one to see the
critical points of the process. Using the knowledge of the im-
purity formation pathways, benidipine production process was
carefully optimized to eliminate or minimize the formation of
impurities, and the amounts of all impurities described in this
article were successfully reduced below 0.10% in the ﬁnal drug
substance. A separate HPLC method was developed and vali-
dated for determination of Ben-2 in benidipine drug substance.
Due to the weakness of the known potentiometric titration
assay method for analysis of the stability samples, a new sta-
bility-indicating UPLC method was developed, validated and
used during analyses of stability samples of benidipine. Stabi-
lity studies were conducted under stress, accelerated and long-
term stability conditions, and benidipine was found sensitive
to oxidizing agents and stable under normal conditions.Acknowledgments
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